Clinical Trials Logo

Polyneuropathies clinical trials

View clinical trials related to Polyneuropathies.

Filter by:
  • Terminated  
  • Page 1 ·  Next »

NCT ID: NCT03779828 Terminated - Clinical trials for Chronic Inflammatory Demyelinating Polyneuropathy

Evaluating the Effectiveness of Telemonitoring System in the Management of Patients With CIDP

HELIPAD 1
Start date: November 27, 2017
Phase:
Study type: Observational

Chronic inflammatory demyelinating polyneuropathy (CIDP) is a chronic demyelinating polyneuropathy of autoimmune origin with a progressive or relapsing course. Diagnosis is based on clinical presentation and electrophysiological findings in accordance with the EFNS/PNS consensus guidelines. IVIg is the first line treatment witch has been shown to be effective in several placebo-controlled trials. Once IVIg therapy produces a response and is well tolerated, some patients are able to continue their treatment in the home setting. The HOME LINK system offers an integrated, global solution based on telemonitoring technology providing continuous, remote monitoring of Privigen® infusions administered at home.

NCT ID: NCT03772717 Terminated - Clinical trials for Chronic Inflammatory Demyelinating Polyneuropathy

Non-invasive Vagus Nerve Stimulation (nVNS) in Pediatric Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

Start date: February 22, 2022
Phase: N/A
Study type: Interventional

Participants will be requested to deliver non-invasive vagus nerve stimulation (nVNS) two times per day, at least five days per week. Participants will be followed for two years with nVNS as an adjunctive therapy to the standard of care therapy for chronic inflammatory demyelinating polyneuropathy (CIDP).

NCT ID: NCT02460107 Terminated - Neuralgia Clinical Trials

Botulinum Toxin Type A for Neuropathic Pain in Patients With Diabetic Peripheral Polyneuropathy

BTXADMPPNP
Start date: May 2015
Phase: Early Phase 1
Study type: Interventional

The purpose of this study is to determine whether botulinum toxin A is effective in the treatment of neuropathic pain in patients with diabetic peripheral polyneuropathy.

NCT ID: NCT01867645 Terminated - Polyneuropathies Clinical Trials

The Impact of IVIG Treatment on Critical Illness Polyneuropathy and/or Myopathy in Patients With MOF and SIRS/Sepsis

CIPNM
Start date: December 2004
Phase: Phase 1
Study type: Interventional

Critical illness polyneuropathy and/or myopathy (CIPNM) is a severe complication of critical illness. Retrospective data suggest that early application of IgM-enriched intravenous immunoglobulin (IVIG) may prevent or mitigate CIPNM. Therefore, the primary objective was to assess the effect of early IgM-enriched IVIG versus placebo to mitigate CIPNM in a prospective setting.

NCT ID: NCT01088256 Terminated - Clinical trials for Postherpetic Neuralgia

Efficacy of Etoricoxib on Peripheral Hyperalgesia

Start date: February 2011
Phase: Phase 2
Study type: Interventional

The purpose of the study is to determine the efficacy of etoricoxib on pain patients. The investigators assume that patients with neuropathic pain will have greater pain relief then patients on placebo.

NCT ID: NCT01063868 Terminated - Clinical trials for Diabetic Polyneuropathy

A Long-term Safety Study With Tapentadol ER and Oxycodone CR in Patients With Moderate to Severe Pain Due to Chronic, Painful Diabetic Peripheral Neuropathy (DPN)

Start date: January 2010
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate the safety profile of orally administered tapentadol ER dosages of 100 to 250 mg twice daily in patients with chronic, painful diabetic peripheral neuropathy (DPN) over long-term exposure of up to 1 year.

NCT ID: NCT00832572 Terminated - Pain Clinical Trials

Study of Ranexa in Patients With Coronary Artery Disease and Painful Polyneuropathy

Start date: January 2009
Phase: Phase 4
Study type: Interventional

This study was to determine whether ranolazine was effective in the treatment of neuropathic pain in patients with coronary artery disease. Eligibility required neurological examination by the study doctor and assessment of the patient's pain. Eligible participants were randomized to receive blinded study medication for a total of 12 weeks.

NCT ID: NCT00508430 Terminated - Clinical trials for Diabetic Neuropathies

ASP 8825 - Study in Patients With Painful Diabetic Polyneuropathy

Start date: July 2007
Phase: Phase 2
Study type: Interventional

To demonstrate the superiority of ASP8825 over placebo and dose response in patients with painful diabetic polyneuropathy.

NCT ID: NCT00228345 Terminated - Clinical trials for Idiopathic Axonal Polyneuropathy

The Significance of Glucose Intolerance in the Pathogenesis of Idiopathic Axonal Polyneuropathy

Start date: January 2004
Phase: Phase 1
Study type: Interventional

The purpose of this study is to determine whether impaired glucose handling (abnormality in the way the body processes blood sugar) can cause a neuropathy (damage to the nerves).

NCT ID: NCT00089557 Terminated - Pain Clinical Trials

An Open-Label Extension Study of NGX-4010 for the Treatment of Neuropathic Pain

Start date: n/a
Phase: Phase 2
Study type: Interventional

This study is an open-label, multicenter, extension study for subjects who completed NeurogesX Study C111 and received treatment with NGX-4010 (Capsaicin Patch) within 12 weeks (up to +7days) before entry into Study C114